Aytu Biopharma (AYTU) Total Debt (2011 - 2026)

Aytu Biopharma (AYTU) has 15 years of Total Debt data on file, last reported at $20.0 million in Q1 2026.

• Total Debt for Q1 2026 came in at $20.0 million, up 75.21% year-over-year; the trailing twelve-month figure through Mar 2026 was $20.0 million (up 75.21% YoY), and the FY2025 annual result was $12.8 million, changed 0.14% from the prior year.
• Total Debt advanced to $20.0 million in Q1 2026 per AYTU's latest filing, from $11.9 million in the prior quarter.
• Over five years, Total Debt peaked at $25.3 million in Q3 2025 and troughed at $1.6 million in Q1 2024.
• A 5-year average of $14.9 million and a median of $14.6 million in 2022 frame the typical range for Total Debt.
• The sharpest annual moves came in 2022 and 2024: Total Debt jumped 2825.33% in 2022, then slumped 92.74% in 2024.
• A 5-year view of Total Debt shows it stood at $14.6 million in 2022, then rose by 9.44% to $16.0 million in 2023, then slipped by 26.02% to $11.8 million in 2024, then climbed by 0.13% to $11.9 million in 2025, then soared by 68.37% to $20.0 million in 2026.
• Business Quant data shows AYTU's Total Debt at $20.0 million in Q1 2026, $11.9 million in Q4 2025, and $25.3 million in Q3 2025.